Veralto Corporation · VLTO · FY2026 Q1 · Calendar Q2 2026
Veralto Raises EPS Guidance on 7% Sales Growth, Announces $1B in Acquisitions
Veralto delivered a strong start to fiscal 2026, beating both EPS and revenue estimates and raising full-year EPS guidance. The quarter was marked by approximately 7% sales growth and 13% adjusted EPS growth, supported by secular demand for water quality solutions and steady packaging demand. Two strategic acquisitions totaling roughly $1 billion — In-Situ in Water Quality and GlobalVision in PQI — broaden the company's capabilities, while a new cost-optimization program targets margin expansion beginning in 2027. Management's confident tone and raised guidance contrast with acknowledged headwinds from tariffs, China municipal softness, and raw-material inflation. The stock's 4.5% post-earnings pop reversed into a 6.7% drift lower over subsequent sessions, suggesting investors may be weighing near-term integration risk and the deferred timeline for cost savings against the positive…
Company context
Snapshot as of publicationVeralto Corporation is a global provider specializing in critical solutions across water quality management, brand protection, and packaging aesthetics. Its operations are structured into two primary divisions: Water Quality (WQ) and Product Quality & Innovation (PQI). The WQ segment delivers advanced instrumentation and treatment technologies designed for the precise measurement, analysis, and purification of water. These solutions cater to a broad spectrum of applications, from residential and commercial settings to municipal systems, industrial processes, research facilities, and natural environments. Esteemed brands like Hach, Trojan Technologies, and ChemTreat fall under this segment, which also supplies essential chemical reagents, support services, and digital tools for comprehensive water management. The PQI segment focuses on enhancing product integrity and brand appeal.…
Earnings scorecard
Reported versus consensusEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| UBS | Neutral | Neutral | Maintain | Jul 30, 2026 |
| Stifel | Buy | Buy | Maintain | Jul 30, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Jul 30, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Jul 30, 2026 |
| BNP Paribas | Outperform | Outperform | Maintain | Jul 30, 2026 |
| Barclays | Overweight | Overweight | Maintain | Jul 30, 2026 |
| Jefferies | Hold | Buy | Downgrade | Dec 10, 2025 |
| BMO Capital | Outperform | Outperform | Maintain | Nov 25, 2025 |
| Baird | Neutral | Neutral | Maintain | Jul 30, 2025 |
| TD Cowen | Hold | Hold | Maintain | Jul 30, 2024 |
| Goldman Sachs | Buy | Buy | Maintain | Jul 29, 2024 |
| Deutsche Bank | Hold | Hold | Maintain | Jul 29, 2024 |
| Vertical Research | Buy | Hold | Upgrade | Oct 16, 2023 |
Named analyst price targets
Upside is calculated against the persisted current price $94.4. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $104 | $94.18 | +10.2% | Jul 30, 2026 |
| Robert W. Baird | Analyst unavailable | $111 | $95.21 | +17.6% | Jul 30, 2026 |
| RBC Capital | Analyst unavailable | $109 | $94.8 | +15.5% | Jul 30, 2026 |
| Stifel Nicolaus | Analyst unavailable | $114 | $98.83 | +20.8% | Jul 30, 2026 |
| Stifel Nicolaus | Analyst unavailable | $111 | $93.81 | +17.6% | Jul 20, 2026 |
| Wolfe Research | Analyst unavailable | $109 | $92.12 | +15.5% | Jul 9, 2026 |
| Robert W. Baird | Michael Halloran | $103 | $89.47 | +9.1% | Apr 30, 2026 |
| Barclays | Analyst unavailable | $113 | $89.47 | +19.7% | Apr 30, 2026 |
| Stifel Nicolaus | Nathan Jones | $110 | $90.85 | +16.5% | Apr 14, 2026 |
| BMO Capital | Analyst unavailable | $108 | $92.81 | +14.4% | Feb 11, 2026 |
| UBS | Joshua Spector | $102 | $91.7 | +8.0% | Feb 6, 2026 |
| Stifel Nicolaus | Nathan Jones | $118 | $90.35 | +25.0% | Feb 5, 2026 |
| RBC Capital | Deane Dray | $102 | $89 | +8.0% | Feb 5, 2026 |
| Robert W. Baird | Michael Halloran | $108 | $91.41 | +14.4% | Feb 5, 2026 |
| Barclays | William Grippin | $117 | $91.41 | +23.9% | Feb 5, 2026 |
| Jefferies | Analyst unavailable | $105 | $98.34 | +11.2% | Dec 10, 2025 |
| BMO Capital | Analyst unavailable | $114 | $103.64 | +20.8% | Nov 25, 2025 |
| RBC Capital | Analyst unavailable | $111 | $100.26 | +17.6% | Oct 30, 2025 |
| Barclays | Analyst unavailable | $121 | $99.5 | +28.2% | Oct 30, 2025 |
| Barclays | William Grippin | $119 | $107.14 | +26.1% | Oct 6, 2025 |
| Barclays | Analyst unavailable | $120 | $107.06 | +27.1% | Sep 18, 2025 |
| Stifel Nicolaus | Analyst unavailable | $120 | $105.78 | +27.1% | Jul 30, 2025 |
| BMO Capital | John McNulty | $119 | $110.46 | +26.1% | Sep 30, 2024 |
| BMO Capital | John McNulty | $117 | $106.28 | +23.9% | Jul 29, 2024 |
| Stifel Nicolaus | Nathan Jones | $117 | $104.87 | +23.9% | Jul 29, 2024 |
| Robert W. Baird | Michael Halloran | $112 | $106.23 | +18.6% | Jul 29, 2024 |
| RBC Capital | Deane Dray | $108 | $106.25 | +14.4% | Jul 29, 2024 |
| Argus Research | John Eade | $110 | $97.27 | +16.5% | May 7, 2024 |
| BMO Capital | John McNulty | $101 | $92.4 | +7.0% | Apr 25, 2024 |
| RBC Capital | Deane Dray | $101 | $92.4 | +7.0% | Apr 25, 2024 |
| Goldman Sachs | Brian Lee | $104 | $89.46 | +10.2% | Mar 22, 2024 |
| RBC Capital | Deane Dray | $78 | $70.74 | -17.4% | Nov 3, 2023 |
Track every rating change on VLTO the moment it posts. Free to start.
Start freeMarket reaction
event-close to next-session closeFollow VLTO with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Compared with the prior quarter, Veralto moved from maintaining full-year guidance to raising its EPS outlook, reflecting stronger-than-expected Q1 execution. The company expanded its acquisition strategy beyond In-Situ (announced in Q4 2025) to include GlobalVision in PQI, bringing total recent acquisition investment to approximately $1 billion. A new cost-optimization program was introduced, with savings not expected to impact 2026 earnings but delivering roughly 50% of run-rate savings in 2027 and full effect by 2028. The effective tax rate declined from approximately 24.5% post-spin to the low-20% range due to tax planning initiatives. Management also flagged new headwinds not emphasized in Q4, including Iran conflict-related commodity cost pressures and Section 232 tariff impacts.
Guidance delta
Veralto raised its full-year 2026 adjusted EPS guidance to a range of $4.20–$4.28, up from the prior outlook. The prior quarter's guidance had assumed low-to-mid single-digit core sales growth, modest margin expansion, and mid-high single-digit EPS growth. The raised EPS outlook reflects Q1 outperformance, with sales growing approximately 7% and adjusted EPS growing 13%. The cost-optimization program's savings are not expected to materially impact 2026 earnings, with the benefit profile back-end loaded into 2027 and 2028. Capex outlook remains stable.
Key takeaways
- Q1 sales grew approximately 7% with adjusted EPS up 13%, beating consensus on both metrics — EPS of $1.07 vs. $1.00 estimated, revenue of $1.42B vs. $1.40B estimated.
- Full-year 2026 EPS guidance was raised to $4.20–$4.28, signaling management confidence in sustained demand.
- Two acquisitions totaling roughly $1 billion (In-Situ in Water Quality, GlobalVision in PQI) broaden the portfolio and add cross-sell opportunities.
- A new cost-optimization program targets a step-change in margins, with approximately 50% of run-rate savings in 2027 and full effect by 2028 — no material 2026 earnings impact.
- Water Quality growth was driven by wastewater reuse and data-center demand, partially offset by continued softness in China municipal water funding.
- The effective tax rate declined to the low-20% range from approximately 24.5% post-spin, providing an additional tailwind.
Management priorities
- Execute disciplined M&A integration of In-Situ and GlobalVision across Water Quality and PQI segments.
- Deliver cost-optimization program savings on schedule, targeting 50% run-rate in 2027 and full effect by 2028.
- Continue share repurchases to return capital to shareholders.
- Expand services for data-center water treatment and digital packaging solutions.
- Maintain pricing discipline amid raw-material inflation and competitor price actions.
Related earnings events
IndustrialsSources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-30T22:31:49.622662+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-30T22:31:49.619615+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.